<ѻýҕl>Novel Combo for Schizophrenia Succeeds in Phase III Trialѻýҕl> Xanomeline-trospium has potential to be first-in-class therapy for schizophrenia if approved Sep 19, 2022
<ѻýҕl>Improvements in Treatment-Resistant Depression With Esketamineѻýҕl> Pooled data from randomized trials showed better scores on the PHQ-9 as well Nov 02, 2021
<ѻýҕl>Lemborexant Helps Insomniacs Catch More Z'sѻýҕl> Even patients with history of depression had better sleep outcomes Nov 02, 2021
<ѻýҕl>Novel Oral Antidepressant Shows Rapid Symptom Improvementѻýҕl> Improvement with 50-mg zuranolone seen by day 3 Nov 02, 2021
<ѻýҕl>Is Earlier Use of Long-Acting Injectable Drugs for Schizophrenia Better?ѻýҕl> Early use linked to fewer inpatient stays and ER visits, study finds Nov 01, 2021
<ѻýҕl>Extended-Release Risperidone Injectable Staves Off Schizophrenia Relapseѻýҕl> Phase III RISE study found benefit with both once-monthly and bimonthly dose Nov 01, 2021
<ѻýҕl>COVID Doesn't Dampen LAI Antipsychotic Prescribing in Schizophreniaѻýҕl> Survey study shows no major changes in prescription trends in 2020 Nov 01, 2021
<ѻýҕl>Migraine Drug Shows Benefit for Those With Comorbid Depression, Anxietyѻýҕl> Real-world study of fremanezumab found that patients were able to reduce antidepressant use Nov 01, 2021
<ѻýҕl>Antipsychotic Patch Quiets Schizophrenia-Related Hostilityѻýҕl> Most significant improvement seen with highest asenapine transdermal dose Oct 31, 2021
<ѻýҕl>Psych Congress 2020: Notable Studiesѻýҕl> Research highlights from the virtual meeting Sep 14, 2020
<ѻýҕl>Trial: Drug Induces, Maintains Dementia-Related Psychosis Remissionѻýҕl> Results pave way for Nuplazid label expansion Sep 14, 2020
<ѻýҕl>Long-Term Gains with Austedo in Tardive Dyskinesiaѻýҕl> Most robust improvement seen in people with more severe disease Sep 13, 2020
<ѻýҕl>Lemborexant Boosts Sleep Outcomes in Insomniaѻýҕl> SUNRISE 2 trial shows better sleep onset, maintenance, and quality Sep 12, 2020
<ѻýҕl>Schizophrenia Tx Eases Depression in Bipolar Disorderѻýҕl> Lumateperone offers greater rate of response, remission versus placebo Sep 12, 2020
<ѻýҕl>Abuse-Deterrent Amphetamine Shines for Adult ADHDѻýҕl> AR19 formulated with physical and chemical barriers against misuse Sep 12, 2020
<ѻýҕl>Add-On Nuplazid Gets a Win in Early Schizophrenia Trialѻýҕl> Phase II study met primary efficacy endpoint Sep 11, 2020
<ѻýҕl>Oral Postpartum Depression Drug Reduces Symptoms for New Momsѻýҕl> Interestingly, drug flopped in a trial last year for major depressive disorder Sep 11, 2020
<ѻýҕl>Overweight Patients Less Likely to Gain Weight on Antipsychoticѻýҕl> Analysis looked at users of brexpiprazole (Rexulti) Oct 07, 2019
<ѻýҕl>Esketamine Nasal Spray Reduces Depression in Suicidal Patientsѻýҕl> Positive results from first global registration program of patients with active suicidal ideation, intent Oct 06, 2019
<ѻýҕl>Novel Combo Tx Shows Durable Antipsychotic Effectsѻýҕl> Almost half of patients with schizophrenia deemed PANSS responders with samidorphan/olanzapine Oct 06, 2019
<ѻýҕl>PM Stimulant Eases Daily Life for Kids With ADHDѻýҕl> Parent-reported outcomes positive with delayed- and extended-release methylphenidate Oct 05, 2019
<ѻýҕl>Injectable vs Oral Antipsychotics: Patients Have Preferencesѻýҕl> Long-acting injectables generally endorsed, but some still favor daily pills Oct 05, 2019